The primary therapeutic role of this medication is applied in addressing symptoms related to physical discomfort and inflammatory or irritative states. As an injectable formulation, it is typically applied in clinical settings that involve acute or unstable symptom patterns, relevant in contexts involving heightened systemic burden. The medication may be part of symptomatic management for moderate to severe pain.

This medication is commonly used across domains where additional symptomatic support is needed, primarily addressing conditions characterized by periods of heightened symptoms such as acute attacks of gout, symptomatic flare-ups of rheumatoid arthritis or ankylosing spondylitis, and pain and inflammation following trauma or surgical procedures (postoperative pain). It is also relevant for easing the severe, spasmodic discomfort associated with visceral conditions, specifically renal colic and biliary colic. The therapeutic use supports the patient during difficult episodes by easing distress.

“This supportive symptomatic management is most often leveraged during acute episodes where pain is pronounced and is commonly used when short-term symptomatic assistance is needed.”

---

Quick Fact: Support for Symptoms related to Acute Pain Imanol may assist with managing pronounced pain and swelling in acute conditions, providing support during difficult symptomatic phases.

Eligibility Map: Who can and cannot use Imanol? — Official Regulatory Information

The following statements define the patient populations for whom Imanol is either officially allowed, restricted, or prohibited, based on regulatory documentation:

Category	Official Regulatory Status
Populations for whom use is allowed	Adult patients (typically ge 18 years old) who do not present any official contraindications or severe organ dysfunction, and who meet the approved eligibility criteria.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the drug or any excipients; individuals with Active Intracranial Bleeding; and patients with pre-existing severe conditions such as Anuria or Severe Pulmonary Edema.
Age-related eligibility rules	Pediatric patients (under 18 years): Safety and effectiveness are not established, meaning use is generally not approved. Geriatric patients (ge 65 years): Use may require increased caution and monitoring due to higher incidence of age-related organ impairment.
Pregnancy and lactation eligibility status	Pregnancy: Use is prohibited (Contraindicated) due to the documented potential for fetal harm. Lactation: Not Recommended; patients must discontinue breastfeeding during treatment and for a specified time thereafter.
Eligibility-related restrictions	Patients with Moderate Hepatic or Renal Impairment require conditional use or a mandatory dose adjustment, as defined in the official prescribing information. Use is also restricted if severe fluid or electrolyte imbalances are not corrected prior to administration.

---

Connection to the overall eligibility profile

Regulatory documents establish the official eligibility profile by using specific criteria to define patient groups that are prohibited from using the medicine (contraindications) versus those for whom use is restricted or not established. This structure ensures the medicine is only used in the population where the benefit-risk balance has been officially verified, preventing use in groups with documented high risk or insufficient safety data.

The official interaction profile for Imanol (Diclofenac) is documented in regulatory labeling, reflecting both pharmacokinetic and pharmacodynamic constraints.

Officially Restricted Combinations

The co-administration of Imanol with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is officially restricted due to a cumulative risk of serious adverse events. The medicine is also formally contraindicated for the management of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Concomitant use with alcohol is documented to increase the risk of serious gastrointestinal bleeding.

Clinically Significant Interaction Patterns

Interactions resulting in Pharmacodynamic Risk Intensification involve combining Imanol with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, SSRIs, or Systemic Corticosteroids, which heightens the risk of gastrointestinal hemorrhage. Exposure Modification occurs as Imanol reduces the renal clearance of agents like Lithium and Methotrexate, resulting in a significant rise in their systemic concentrations. Conversely, co-administration with a strong CYP inhibitor (e.g., Voriconazole) is documented to increase Imanol's own plasma exposure. Furthermore, combining with Diuretics or ACE Inhibitors/ARBs may diminish their intended therapeutic effects and raises the risk of renal impairment.

Blocking the Prostaglandin Synthesis Pathway

Imanol acts as a non-selective Cyclooxygenase (COX) enzyme inhibitor, preferentially targeting the COX-2 isoform responsible for generating inflammatory mediators. By blocking this enzyme's activity, the drug curtails the conversion of arachidonic acid into prostaglandins—the key chemical messengers that drive the inflammatory cascade. This molecular step directly initiates the resulting physiological consequences.

Modulation of Nociceptive Signal Transduction

The suppression of prostaglandin synthesis inhibits these mediators from sensitizing peripheral pain receptors (nociceptors) at the site of tissue injury. This results in the physiological consequence of reduced nociceptor sensitization, reflecting a decrease in the responsiveness of nerve endings to stimuli.

Influence on Central Thermoregulatory Signaling ️

A related mechanistic domain involves the drug's influence on the brain's temperature control center. By limiting the concentration of fever-inducing prostaglandins within the hypothalamus, the drug supports a reversal of the elevated temperature set-point caused by upstream mediators. This central action contributes to the resulting physiological consequence of a lowering of the hypothalamic temperature set-point.

How to Use Imanol: Official Administration Guidelines

Imanol is the injectable formulation of Diclofenac, and its use is strictly governed by established procedural protocols. These instructions define the administration route, precise dosing, and duration constraints for this medicine.

---

Official Administration Scope

Imanol is administered via two primary parenteral routes: Intramuscular (IM) Injection (deep intragluteal) and Intravenous (IV) Infusion (slow infusion in a supervised setting). The official dosing schedule dictates that the total daily dosage must not exceed 150 mg, regardless of the route of administration. The standard IM dose is typically 75 mg once daily, which may be repeated in severe cases, provided the total daily limit is observed.

---

Preparation and Duration Constraints

Administration of the IV infusion requires specific preparation: the solution must be diluted immediately before use with an approved diluent, such as 0.9% sodium chloride or 5% glucose solution, and must be buffered with sodium bicarbonate. The injection is explicitly restricted in its duration of use; the injectable form should not be given for more than two days. If further analgesic or anti-inflammatory management is necessary beyond this period, the treatment must transition to oral or rectal dosage forms.

---

Population and Procedural Rules

Specific use rules exist for certain populations. For older adults, the instruction is to utilize the lowest effective dose for the shortest duration possible. Furthermore, the injectable form is generally not recommended for use in children. Procedurally, the contents of the ampoule must not be mixed with any other solutions (outside of the specified buffered diluents) due to documented incompatibilities.

Recent Clinical Evidence / Overview of Studies

Initial Research Context

Clinical research involving Imanol has primarily focused on its potential role as a maintenance treatment in specific patient populations. Studies explored the substance in the context of advanced disease management, particularly after patients have achieved stabilization or response following initial chemotherapy.

Phase II Trial Findings (The SOGUG-IMANOL Study)

A key investigation, the SOGUG-IMANOL trial, was a Phase II, non-comparative, Spanish multicenter study. It examined the use of the drug as maintenance therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) who had achieved a partial response or disease stabilization following docetaxel chemotherapy. Enrollment was limited to patients identified as harboring a homologous recombination repair (HRR) gene mutation.

Trial participants received the study drug over a continuous period. Primary findings reported a median radiographic progression-free survival (PFS) of 11.1 months (95% CI, 5.7 to 16.5 months) in the small cohort evaluated. Clinical benefit, defined as partial response or stable disease, was observed in the majority of patients in the study group.

Safety and Data Gaps

Adverse events were reported and generally considered manageable. The most common Grade 3 or higher events observed were asthenia (fatigue), anemia, and neutropenia. As a non-comparative Phase II study, the current evidence is limited, and these findings require confirmation in larger, randomized, controlled trials. Data regarding the drug's long-term safety profile and potential interactions with other common medications remain limited.

Common questions about Imanol (FAQ)

---

Q: Can I take Imanol with common pain relievers like ibuprofen or Tylenol?

Official documents restrict combining Imanol with other NSAIDs (Nonsteroidal Anti-inflammatory Drugs) such as ibuprofen due to an increased risk of serious side effects. While no specific interaction is noted with Acetaminophen (Tylenol), the official information directs that any such combination requires evaluation by a healthcare provider.

---

Q: Is Imanol safe for long-term use?

Regulatory agencies document that the risk of serious side effects, particularly cardiovascular events (such as heart attack or stroke) and gastrointestinal bleeding, generally increases with the duration of use and higher doses. The injectable form is restricted to short-term use—typically no more than two days—and treatment is transitioned to non-injectable forms thereafter, according to official guidelines.

---

Q: Are there any specific foods or drinks I need to avoid while on Imanol?

Official patient information generally suggests taking the medicine with food, a snack, or milk to help minimize the possibility of stomach discomfort. No specific non-alcoholic food or drink items are officially required to be avoided.

---

Q: What kind of studies were done on Imanol before it was approved?

The drug was initially approved based on clinical trials that provided evidence of its intended therapeutic effect for the relief of pain and inflammation. These studies established its initial safety profile as required by regulatory authorities for new NSAID products.

---

Q: Is the research evidence for Imanol considered strong?

Evidence supports the drug's use for its officially approved indications. However, some clinical data has led regulatory bodies to issue and update warnings regarding potential risks, such as cardiovascular events, which may be more pronounced with long-term or high-dose use.

---

Q: Are there different strengths or forms (e.g., tablet vs. liquid) of Imanol available?

The active ingredient in Imanol, Diclofenac, is available in various forms beyond the injection. These include oral tablets (such as immediate-release, delayed-release, and extended-release), rectal suppositories, and topical applications.

---

Q: Is Imanol a prescription drug or can I get it over the counter?

Imanol (Diclofenac sodium injection) is officially classified as a prescription-only medicine and is not available over the counter.

---

Q: How long does it typically take for Imanol to start working?

Pharmacological data indicates that the onset of effect for the injectable form is rapid, with initial effects typically measured within approximately 30 minutes of administration.

---

Q: Can Imanol cause weight gain or weight loss?

Official safety information lists 'weight changes' as an occasional reported side effect. Fluid retention and edema are also separately documented as possible adverse events.

---

Q: What happens if I miss a scheduled dose of Imanol?

Official patient instructions describe that if a dose is missed, it should be taken as soon as possible. However, if the time for the next dose is almost due, the missed dose should be skipped entirely. Official patient instructions indicate that a missed dose should not be supplemented by taking two doses at once.

---

Q: Is it safe to take Imanol if I have high blood pressure?

Regulatory documentation requires careful consideration and monitoring for patients with existing high blood pressure (hypertension). This caution is due to the drug’s documented cardiovascular risks and the potential for it to cause fluid retention.

---

Q: Are there restrictions on driving or operating machinery while taking Imanol?

Official warnings describe that patients should refrain from driving or operating machinery if side effects such as dizziness, tiredness, sleepiness, or vision problems are experienced.

---

Q: Does Imanol show up on standard drug tests?

Imanol (Diclofenac) is not a controlled substance under government regulations. For this reason, it is not generally screened for on standard workplace or regulatory drug tests designed to detect illicit or controlled narcotic substances.

---

Q: How is Imanol different from the generic version?

Regulatory standards require the generic version to contain the exact same active ingredient (Diclofenac) and work in the same way. However, the generic may differ in its inactive ingredients (excipients) or the proprietary formulation technology used to create the medicine.

---

Q: Can Imanol interact with herbal supplements like St. John's wort?

Imanol is eliminated from the body using a liver enzyme (CYP2C9). Official documents note that some herbal supplements, such as St. John's wort, can affect this system, potentially changing the drug's concentration in the body.

---

Q: Does Imanol affect sleep or cause insomnia?

Official safety information lists insomnia (difficulty sleeping), as well as general tiredness and drowsiness, as possible reported side effects affecting the nervous system.

---

Q: Is Imanol a controlled substance?

Imanol (Diclofenac) is not classified as a narcotic or a controlled substance under government regulations.

---

Q: How long does Imanol stay in your system after stopping treatment?

Pharmacokinetic data provides information on how the body processes the drug. The terminal half-life of the active ingredient (Diclofenac) is described as short, typically in the range of 1.2 to 2 hours.

---

Q: Does Imanol cause dependency or withdrawal symptoms if stopped suddenly?

Imanol is not classified as a controlled substance. It is not described in official documentation as having the potential for dependency or withdrawal symptoms commonly associated with narcotic or opioid medications.

--UN-

Q: Are there specific symptoms that mean I need to stop taking Imanol right away?

Official documentation emphasizes that certain serious symptoms—such as signs of cardiovascular events (like sudden chest pain) or gastrointestinal events (like black or bloody stools or severe stomach pain)—are documented and require prompt evaluation by a healthcare provider.

---

Q: Does Imanol affect mood or cause emotional changes?

Official safety information lists changes in mood, including anxiety, confusion, and depression, as possible reported side effects affecting the nervous system.

---

Q: Can I take Imanol if I have a history of depression or anxiety?

Official safety information includes reports of mood changes, such as anxiety and depression, as potential side effects. Patients with a history of these conditions are often monitored closely for any changes during treatment.

---

Q: Can Imanol be taken with food, or does it need to be taken on an empty stomach?

Official patient information typically specifies that the medicine may be administered with food, a snack, or milk, which is intended to help reduce the possibility of stomach irritation.

The storage and disposal of Imanol (Diclofenac sodium injection) must strictly follow official regulatory requirements to ensure product stability.

Storage Requirements

Imanol must be stored at or below 30 C and protected from light by keeping the ampoules in their original outer carton. The solution must not be refrigerated or frozen as this can compromise its stability. The product should be stored locked up and kept out of the sight and reach of children.

Stability and Handling

This medicine is provided in a single-dose container and must be used immediately upon opening. Any unused portion of the solution must be discarded. If the solution is diluted for infusion, it must also be used immediately.

Disposal Instructions

Expired or unused Imanol must be disposed of in accordance with local and national regulations. The medicine must not be released into wastewater. Official guidance recommends using authorized drug take-back programs or following approved household disposal steps, such as mixing the medicine with an undesirable substance before discarding it in the trash.